Crispr Therapeutics AG vs Wayfair Inc — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.23B), while Wayfair Inc trades at $103.75 (market cap $14.14B). The key difference: Wayfair Inc is far larger — about 2.7× Crispr Therapeutics AG's market cap, and Wayfair Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | W | |
|---|---|---|
Market Cap | $5.23B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $119.05 |
52-Week Low | $44.34 | $57.40 |
Enterprise Value | $3.65B | $16.47B |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →